-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
CI-39
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2132412-25-8.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2132412-25-8 |
| Description | CI-39 is an antiviral natural product. CI-39 is an NNRTI (non-nucleoside reverse transcriptase inhibit) antiviral agent with an EC50 of 3.40 µM and an CC50 of >30 µM for wild type HIV-1. CI-39 inhibits HIV-1 RT DNA polymerase and ribonuclease H activitiessup. |
Product Information
| Synonyms | CI-39|CHEMBL4792750|HY-146364|CS-0498478|methyl 2-[[2-(1-methoxyindol-3-yl)acetyl]amino]benzoate |
| Molecular Weight | 338.36 |
| Molecular Formula | C19H18N2O4 |
| Canonical SMILES | COC(=O)C1=CC=CC=C1NC(=O)CC2=CN(C3=CC=CC=C32)OC |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 484 |
| Exact Mass | 338.12665706 |
| In Vitro | CI-39 (0-100 µM) inhibits HIV-1 RT DNA polymerase and ribonuclease H activities with EC50s of 7.20, >30 µM, respectively. CI-39 shows antiviral activities with EC50s of 3.37, 3.00, 2.41, 3.08, 2.14, 3.27, 3.19, 4.07 µM for VSVG/HIV-1wt, VSVG/HIV-1RT-K103N, VSVG/HIV-1wtRT-K103N, VSVG/HIV-1RT-K1RT-Y181C, VSVG/HIV-1RT-K1RT-K103N,Y181C, VSVG/HIV-1RT-K103N,Y181C, VSVG/HIV-1RT-L100I,K103N, VSVG/HIV-1RT-Y188L, VSVG/HIV-1RT-K103N,G190A, VSVG/HIV-1RT-K103N,V108I, respectively. |
| Target | HIV-1 (WT): 3.40 μM (EC50) HIV-1 (WT): >30 μM (CC50) |
| XLogP3-AA | 3.6 |
